ID   EPHA2_HUMAN             Reviewed;         976 AA.
AC   P29317; B5A968; Q8N3Z2;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 2.
DT   12-OCT-2022, entry version 243.
DE   RecName: Full=Ephrin type-A receptor 2;
DE            EC=2.7.10.1;
DE   AltName: Full=Epithelial cell kinase;
DE   AltName: Full=Tyrosine-protein kinase receptor ECK;
DE   Flags: Precursor;
GN   Name=EPHA2; Synonyms=ECK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), CATALYTIC ACTIVITY, AND
RP   AUTOPHOSPHORYLATION.
RC   TISSUE=Epithelium;
RX   PubMed=2174105; DOI=10.1128/mcb.10.12.6316-6324.1990;
RA   Lindberg R.A., Hunter T.;
RT   "cDNA cloning and characterization of eck, an epithelial cell receptor
RT   protein-tyrosine kinase in the eph/elk family of protein kinases.";
RL   Mol. Cell. Biol. 10:6316-6324(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RX   PubMed=18593464; DOI=10.1186/ar2447;
RA   Jin P., Zhang J., Sumariwalla P.F., Ni I., Jorgensen B., Crawford D.,
RA   Phillips S., Feldmann M., Shepard H.M., Paleolog E.M.;
RT   "Novel splice variants derived from the receptor tyrosine kinase
RT   superfamily are potential therapeutics for rheumatoid arthritis.";
RL   Arthritis Res. Ther. 10:R73-R73(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NOMENCLATURE.
RX   PubMed=9267020; DOI=10.1016/s0092-8674(00)80500-0;
RG   Eph nomenclature committee;
RT   "Unified nomenclature for Eph family receptors and their ligands, the
RT   ephrins.";
RL   Cell 90:403-404(1997).
RN   [7]
RP   FUNCTION IN INTEGRIN-MEDIATED CELL ADHESION, FUNCTION IN CELL MIGRATION,
RP   PHOSPHORYLATION, INTERACTION WITH PTK2/FAK1 AND PTPN11, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10655584; DOI=10.1038/35000008;
RA   Miao H., Burnett E., Kinch M., Simon E., Wang B.;
RT   "Activation of EphA2 kinase suppresses integrin function and causes focal-
RT   adhesion-kinase dephosphorylation.";
RL   Nat. Cell Biol. 2:62-69(2000).
RN   [8]
RP   ONCOGENICITY.
RX   PubMed=11280802;
RA   Zelinski D.P., Zantek N.D., Stewart J.C., Irizarry A.R., Kinch M.S.;
RT   "EphA2 overexpression causes tumorigenesis of mammary epithelial cells.";
RL   Cancer Res. 61:2301-2306(2001).
RN   [9]
RP   INTERACTION WITH ACP1, AND DEPHOSPHORYLATION BY ACP1.
RX   PubMed=12167657; DOI=10.1074/jbc.m207127200;
RA   Kikawa K.D., Vidale D.R., Van Etten R.L., Kinch M.S.;
RT   "Regulation of the EphA2 kinase by the low molecular weight tyrosine
RT   phosphatase induces transformation.";
RL   J. Biol. Chem. 277:39274-39279(2002).
RN   [10]
RP   FUNCTION IN CELL-CELL INTERACTION, INTERACTION WITH CLDN4, AND MUTAGENESIS
RP   OF LYS-646.
RX   PubMed=16236711; DOI=10.1074/jbc.m503786200;
RA   Tanaka M., Kamata R., Sakai R.;
RT   "EphA2 phosphorylates the cytoplasmic tail of Claudin-4 and mediates
RT   paracellular permeability.";
RL   J. Biol. Chem. 280:42375-42382(2005).
RN   [11]
RP   TISSUE SPECIFICITY.
RX   PubMed=17332925;
RA   Liu D.-P., Wang Y., Koeffler H.P., Xie D.;
RT   "Ephrin-A1 is a negative regulator in glioma through down-regulation of
RT   EphA2 and FAK.";
RL   Int. J. Oncol. 30:865-871(2007).
RN   [12]
RP   INTERACTION WITH INPPL1.
RX   PubMed=17135240; DOI=10.1074/jbc.m608509200;
RA   Zhuang G., Hunter S., Hwang Y., Chen J.;
RT   "Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via
RT   phosphatidylinositol 3-Kinase-dependent Rac1 activation.";
RL   J. Biol. Chem. 282:2683-2694(2007).
RN   [13]
RP   FUNCTION IN APOPTOSIS, AND INDUCTION BY UV.
RX   PubMed=18339848; DOI=10.1158/0008-5472.can-07-2372;
RA   Zhang G., Njauw C.-N., Park J.M., Naruse C., Asano M., Tsao H.;
RT   "EphA2 is an essential mediator of UV radiation-induced apoptosis.";
RL   Cancer Res. 68:1691-1696(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-579 AND THR-647, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=18794797; DOI=10.1038/onc.2008.328;
RA   Wykosky J., Palma E., Gibo D.M., Ringler S., Turner C.P., Debinski W.;
RT   "Soluble monomeric EphrinA1 is released from tumor cells and is a
RT   functional ligand for the EphA2 receptor.";
RL   Oncogene 27:7260-7273(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; SER-892 AND SER-901, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   DISEASE, FUNCTION IN CELL MIGRATION, SUBCELLULAR LOCATION, MUTAGENESIS OF
RP   ASP-739 AND SER-897, AND PHOSPHORYLATION AT SER-897 BY PKB.
RX   PubMed=19573808; DOI=10.1016/j.ccr.2009.04.009;
RA   Miao H., Li D.Q., Mukherjee A., Guo H., Petty A., Cutter J., Basilion J.P.,
RA   Sedor J., Wu J., Danielpour D., Sloan A.E., Cohen M.L., Wang B.;
RT   "EphA2 mediates ligand-dependent inhibition and ligand-independent
RT   promotion of cell migration and invasion via a reciprocal regulatory loop
RT   with Akt.";
RL   Cancer Cell 16:9-20(2009).
RN   [18]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-435.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [19]
RP   UBIQUITINATION BY STUB1.
RX   PubMed=19567782; DOI=10.1158/1541-7786.mcr-08-0582;
RA   Annamalai B., Liu X., Gopal U., Isaacs J.S.;
RT   "Hsp90 is an essential regulator of EphA2 receptor stability and signaling:
RT   implications for cancer cell migration and metastasis.";
RL   Mol. Cancer Res. 7:1021-1032(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-570; TYR-628; THR-647 AND
RP   SER-869, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   FUNCTION IN CELL MIGRATION, AND INTERACTION WITH ARHGEF16; DOCK4 AND ELMO2.
RX   PubMed=20679435; DOI=10.1083/jcb.201005141;
RA   Hiramoto-Yamaki N., Takeuchi S., Ueda S., Harada K., Fujimoto S.,
RA   Negishi M., Katoh H.;
RT   "Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent
RT   mechanism.";
RL   J. Cell Biol. 190:461-477(2010).
RN   [22]
RP   FUNCTION IN KERATINOCYTE ADHESION AND DIFFERENTIATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=20861311; DOI=10.1091/mbc.e10-03-0242;
RA   Lin S., Gordon K., Kaplan N., Getsios S.;
RT   "Ligand targeting of EphA2 enhances keratinocyte adhesion and
RT   differentiation via desmoglein 1.";
RL   Mol. Biol. Cell 21:3902-3914(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20223987; DOI=10.1126/science.1181729;
RA   Salaita K., Nair P.M., Petit R.S., Neve R.M., Das D., Gray J.W.,
RA   Groves J.T.;
RT   "Restriction of receptor movement alters cellular response: physical force
RT   sensing by EphA2.";
RL   Science 327:1380-1385(2010).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [26]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=21516087; DOI=10.1038/nm.2341;
RA   Lupberger J., Zeisel M.B., Xiao F., Thumann C., Fofana I., Zona L.,
RA   Davis C., Mee C.J., Turek M., Gorke S., Royer C., Fischer B., Zahid M.N.,
RA   Lavillette D., Fresquet J., Cosset F.L., Rothenberg S.M., Pietschmann T.,
RA   Patel A.H., Pessaux P., Doffoel M., Raffelsberger W., Poch O.,
RA   McKeating J.A., Brino L., Baumert T.F.;
RT   "EGFR and EphA2 are host factors for hepatitis C virus entry and possible
RT   targets for antiviral therapy.";
RL   Nat. Med. 17:589-595(2011).
RN   [27]
RP   INTERACTION WITH ANKS1A.
RX   PubMed=22332920; DOI=10.1021/bi300141h;
RA   Mercurio F.A., Marasco D., Pirone L., Pedone E.M., Pellecchia M., Leone M.;
RT   "Solution structure of the first Sam domain of Odin and binding studies
RT   with the EphA2 receptor.";
RL   Biochemistry 51:2136-2145(2012).
RN   [28]
RP   INTERACTION WITH HHV-8 GLYCOPROTEIN L/GLYCOPROTEIN H (MICROBIAL INFECTION).
RX   PubMed=22635007; DOI=10.1038/nm.2805;
RA   Hahn A.S., Kaufmann J.K., Wies E., Naschberger E., Panteleev-Ivlev J.,
RA   Schmidt K., Holzer A., Schmidt M., Chen J., Konig S., Ensser A., Myoung J.,
RA   Brockmeyer N.H., Sturzl M., Fleckenstein B., Neipel F.;
RT   "The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's
RT   sarcoma-associated herpesvirus.";
RL   Nat. Med. 18:961-966(2012).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-575; SER-892; SER-897 AND
RP   SER-901, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   FUNCTION IN CELL MIGRATION, PHOSPHORYLATION AT TYR-930, DEPHOSPHORYLATION
RP   AT TYR-930 BY PTPRF, AND INTERACTION WITH NCK1.
RX   PubMed=23358419; DOI=10.1128/mcb.01708-12;
RA   Lee H., Bennett A.M.;
RT   "Receptor protein tyrosine phosphatase-receptor tyrosine kinase substrate
RT   screen identifies EphA2 as a target for LAR in cell migration.";
RL   Mol. Cell. Biol. 33:1430-1441(2013).
RN   [31]
RP   INTERACTION WITH CEMIP.
RX   PubMed=23936024; DOI=10.1371/journal.pone.0069473;
RA   Tiwari A., Schneider M., Fiorino A., Haider R., Okoniewski M.J.,
RA   Roschitzki B., Uzozie A., Menigatti M., Jiricny J., Marra G.;
RT   "Early insights into the function of KIAA1199, a markedly overexpressed
RT   protein in human colorectal tumors.";
RL   PLoS ONE 8:E69473-E69473(2013).
RN   [32]
RP   PHOSPHORYLATION AT SER-897 BY RPS6KA1 AND RPS6KA3, AND FUNCTION IN CELL
RP   MIGRATION.
RX   PubMed=26158630; DOI=10.1038/ncomms8679;
RA   Zhou Y., Yamada N., Tanaka T., Hori T., Yokoyama S., Hayakawa Y., Yano S.,
RA   Fukuoka J., Koizumi K., Saiki I., Sakurai H.;
RT   "Crucial roles of RSK in cell motility by catalysing serine phosphorylation
RT   of EphA2.";
RL   Nat. Commun. 6:7679-7679(2015).
RN   [33]
RP   PHOSPHORYLATION AT SER-897 BY PKA, PHOSPHORYLATION AT SER-901, AND
RP   FUNCTION.
RX   PubMed=27385333; DOI=10.1091/mbc.e16-01-0048;
RA   Barquilla A., Lamberto I., Noberini R., Heynen-Genel S., Brill L.M.,
RA   Pasquale E.B.;
RT   "Protein kinase A can block EphA2 receptor-mediated cell repulsion by
RT   increasing EphA2 S897 phosphorylation.";
RL   Mol. Biol. Cell 27:2757-2770(2016).
RN   [34]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H
RP   (MICROBIAL INFECTION).
RX   PubMed=29292383; DOI=10.1038/s41564-017-0080-8;
RA   Zhang H., Li Y., Wang H.B., Zhang A., Chen M.L., Fang Z.X., Dong X.D.,
RA   Li S.B., Du Y., Xiong D., He J.Y., Li M.Z., Liu Y.M., Zhou A.J., Zhong Q.,
RA   Zeng Y.X., Kieff E., Zhang Z., Gewurz B.E., Zhao B., Zeng M.S.;
RT   "Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus
RT   entry.";
RL   Nat. Microbiol. 3:1-8(2018).
RN   [35]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS/HHV-4 GLYCOPROTEIN L/GLYCOPROTEIN H
RP   (MICROBIAL INFECTION).
RX   PubMed=29292384; DOI=10.1038/s41564-017-0081-7;
RA   Chen J., Sathiyamoorthy K., Zhang X., Schaller S., Perez White B.E.,
RA   Jardetzky T.S., Longnecker R.;
RT   "Ephrin receptor A2 is a functional entry receptor for Epstein-Barr
RT   virus.";
RL   Nat. Microbiol. 3:172-180(2018).
RN   [36]
RP   INTERACTION WITH TIMD4, AND SUBCELLULAR LOCATION.
RX   PubMed=34067457; DOI=10.3390/cells10061290;
RA   Moon B., Yang S., Kim K., Lee J., Jeong D., Park D.;
RT   "EphA2 Interacts with Tim-4 through Association between Its FN3 Domain and
RT   the IgV Domain of Tim-4.";
RL   Cells 10:0-0(2021).
RN   [37]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 596-900.
RX   PubMed=12467573; DOI=10.1016/s0969-2126(02)00907-3;
RA   Nowakowski J., Cronin C.N., McRee D.E., Knuth M.W., Nelson C.G.,
RA   Pavletich N.P., Rogers J., Sang B.C., Scheibe D.N., Swanson R.V.,
RA   Thompson D.A.;
RT   "Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases
RT   from nanovolume crystallography.";
RL   Structure 10:1659-1667(2002).
RN   [38]
RP   STRUCTURE BY NMR OF 902-976.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the C-terminal SAM-domain of EPHAA2: ephrin type-A
RT   receptor 2 precursor (EC 2.7.10.1).";
RL   Submitted (JAN-2008) to the PDB data bank.
RN   [39]
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 28-201, X-RAY CRYSTALLOGRAPHY
RP   (2.0 ANGSTROMS) OF 28-201 IN COMPLEX WITH EFNA1, SUBUNIT, DISULFIDE BOND,
RP   AND MUTAGENESIS OF ARG-103.
RX   PubMed=19525919; DOI=10.1038/embor.2009.91;
RA   Himanen J.P., Goldgur Y., Miao H., Myshkin E., Guo H., Buck M., Nguyen M.,
RA   Rajashankar K.R., Wang B., Nikolov D.B.;
RT   "Ligand recognition by A-class Eph receptors: crystal structures of the
RT   EphA2 ligand-binding domain and the EphA2/ephrin-A1 complex.";
RL   EMBO Rep. 10:722-728(2009).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 25-202, AND DISULFIDE BOND.
RG   Structural genomics consortium (SGC);
RT   "Ephrin A1 bound to the ligand binding domain of the human ephrin A2
RT   (EPHA2) receptor protein kinase.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [41]
RP   STRUCTURE BY NMR OF 523-563.
RA   Mayzel M.L., Bocharov E.V., Volynsky P.E., Arseniev A.S.;
RT   "Left-handed dimer of EPHA2 transmembrane domain helix packing diversity
RT   among receptor tyrosine kinases.";
RL   Submitted (AUG-2009) to the PDB data bank.
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 23-202 IN COMPLEX WITH EFNA1, AND
RP   SUBUNIT.
RX   PubMed=20505120; DOI=10.1073/pnas.1004148107;
RA   Himanen J.P., Yermekbayeva L., Janes P.W., Walker J.R., Xu K., Atapattu L.,
RA   Rajashankar K.R., Mensinga A., Lackmann M., Nikolov D.B., Dhe-Paganon S.;
RT   "Architecture of Eph receptor clusters.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:10860-10865(2010).
RN   [43]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-391; MET-511; HIS-568; SER-777 AND
RP   HIS-876.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [44]
RP   VARIANT CTRCT6 TRP-948.
RX   PubMed=19005574;
RA   Shiels A., Bennett T.M., Knopf H.L.S., Maraini G., Li A., Jiao X.,
RA   Hejtmancik J.F.;
RT   "The EPHA2 gene is associated with cataracts linked to chromosome 1p.";
RL   Mol. Vis. 14:2042-2055(2008).
RN   [45]
RP   VARIANT CTRCT6 ILE-940.
RX   PubMed=19306328; DOI=10.1002/humu.20995;
RA   Zhang T., Hua R., Xiao W., Burdon K.P., Bhattacharya S.S., Craig J.E.,
RA   Shang D., Zhao X., Mackey D.A., Moore A.T., Luo Y., Zhang J., Zhang X.;
RT   "Mutations of the EPHA2 receptor tyrosine kinase gene cause autosomal
RT   dominant congenital cataract.";
RL   Hum. Mutat. 30:E603-E611(2009).
RN   [46]
RP   VARIANT CTRCT6 GLN-721, AND CHARACTERIZATION OF VARIANT CTRCT6 GLN-721.
RX   PubMed=19649315; DOI=10.1371/journal.pgen.1000584;
RA   Jun G., Guo H., Klein B.E., Klein R., Wang J.J., Mitchell P., Miao H.,
RA   Lee K.E., Joshi T., Buck M., Chugha P., Bardenstein D., Klein A.P.,
RA   Bailey-Wilson J.E., Gong X., Spector T.D., Andrew T., Hammond C.J.,
RA   Elston R.C., Iyengar S.K., Wang B.;
RT   "EPHA2 is associated with age-related cortical cataract in mice and
RT   humans.";
RL   PLoS Genet. 5:E1000584-E1000584(2009).
RN   [47]
RP   CHARACTERIZATION OF VARIANTS CTRCT6 ILE-940 AND CTRCT6 TRP-948.
RX   PubMed=22570727; DOI=10.1371/journal.pone.0036564;
RA   Park J.E., Son A.I., Hua R., Wang L., Zhang X., Zhou R.;
RT   "Human cataract mutations in EPHA2 SAM domain alter receptor stability and
RT   function.";
RL   PLoS ONE 7:E36564-E36564(2012).
CC   -!- FUNCTION: Receptor tyrosine kinase which binds promiscuously membrane-
CC       bound ephrin-A family ligands residing on adjacent cells, leading to
CC       contact-dependent bidirectional signaling into neighboring cells. The
CC       signaling pathway downstream of the receptor is referred to as forward
CC       signaling while the signaling pathway downstream of the ephrin ligand
CC       is referred to as reverse signaling. Activated by the ligand ephrin-
CC       A1/EFNA1 regulates migration, integrin-mediated adhesion, proliferation
CC       and differentiation of cells. Regulates cell adhesion and
CC       differentiation through DSG1/desmoglein-1 and inhibition of the
CC       ERK1/ERK2 (MAPK3/MAPK1, respectively) signaling pathway. May also
CC       participate in UV radiation-induced apoptosis and have a ligand-
CC       independent stimulatory effect on chemotactic cell migration. During
CC       development, may function in distinctive aspects of pattern formation
CC       and subsequently in development of several fetal tissues. Involved for
CC       instance in angiogenesis, in early hindbrain development and epithelial
CC       proliferation and branching morphogenesis during mammary gland
CC       development. Engaged by the ligand ephrin-A5/EFNA5 may regulate lens
CC       fiber cells shape and interactions and be important for lens
CC       transparency development and maintenance. With ephrin-A2/EFNA2 may play
CC       a role in bone remodeling through regulation of osteoclastogenesis and
CC       osteoblastogenesis. {ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:16236711, ECO:0000269|PubMed:18339848,
CC       ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20679435,
CC       ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:23358419,
CC       ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for hepatitis C
CC       virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV
CC       entry by promoting the formation of the CD81-CLDN1 receptor complexes
CC       that are essential for HCV entry and by enhancing membrane fusion of
CC       cells expressing HCV envelope glycoproteins.
CC       {ECO:0000269|PubMed:21516087}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:2174105};
CC   -!- SUBUNIT: Homodimer. Interacts with SLA. Interacts (phosphorylated form)
CC       with VAV2, VAV3 and PI3-kinase p85 subunit (PIK3R1, PIK3R2 or PIK3R3);
CC       critical for the EFNA1-induced activation of RAC1 which stimulates cell
CC       migration (By similarity). Interacts with INPPL1; regulates activated
CC       EPHA2 endocytosis and degradation. Interacts (inactivated form) with
CC       PTK2/FAK1 and interacts (EFNA1 ligand-activated form) with PTPN11;
CC       regulates integrin-mediated adhesion. Interacts with ARHGEF16, DOCK4
CC       and ELMO2; mediates ligand-independent activation of RAC1 which
CC       stimulates cell migration. Interacts with CLDN4; phosphorylates CLDN4
CC       and may regulate tight junctions. Interacts with ACP1. Interacts (via
CC       SAM domain) with ANKS1A (via SAM domain). Interacts with CEMIP.
CC       Interacts with NCK1; may regulate EPHA2 activity in cell migration and
CC       adhesion. Interacts with TIMD4 (PubMed:34067457).
CC       {ECO:0000250|UniProtKB:Q03145, ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:12167657, ECO:0000269|PubMed:16236711,
CC       ECO:0000269|PubMed:17135240, ECO:0000269|PubMed:19525919,
CC       ECO:0000269|PubMed:20505120, ECO:0000269|PubMed:20679435,
CC       ECO:0000269|PubMed:22332920, ECO:0000269|PubMed:23358419,
CC       ECO:0000269|PubMed:23936024, ECO:0000269|PubMed:34067457}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human herpes virus 8/HHV-
CC       8 glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction
CC       triggers EPHA2 phosphorylation and endocytosis, allowing virus entry.
CC       {ECO:0000269|PubMed:22635007}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Epstein-Barr virus/HHV-4
CC       glycoprotein L/gL and glycoprotein H/gH heterodimer; this interaction
CC       facilitates virus internalization and fusion.
CC       {ECO:0000269|PubMed:29292383, ECO:0000269|PubMed:29292384}.
CC   -!- INTERACTION:
CC       P29317; P30530: AXL; NbExp=2; IntAct=EBI-702104, EBI-2850927;
CC       P29317; P35222: CTNNB1; NbExp=2; IntAct=EBI-702104, EBI-491549;
CC       P29317; P20827: EFNA1; NbExp=9; IntAct=EBI-702104, EBI-715194;
CC       P29317; P52803: EFNA5; NbExp=6; IntAct=EBI-702104, EBI-1753674;
CC       P29317; P29320: EPHA3; NbExp=3; IntAct=EBI-702104, EBI-1641575;
CC       P29317; P54756: EPHA5; NbExp=3; IntAct=EBI-702104, EBI-1383718;
CC       P29317; Q9UF33: EPHA6; NbExp=3; IntAct=EBI-702104, EBI-3950019;
CC       P29317; Q15375: EPHA7; NbExp=6; IntAct=EBI-702104, EBI-1383428;
CC       P29317; P08238: HSP90AB1; NbExp=2; IntAct=EBI-702104, EBI-352572;
CC       P29317; O15357-1: INPPL1; NbExp=3; IntAct=EBI-702104, EBI-15963021;
CC       P29317; P29376: LTK; NbExp=2; IntAct=EBI-702104, EBI-6596163;
CC       P29317; Q05397: PTK2; NbExp=3; IntAct=EBI-702104, EBI-702142;
CC       P29317; Q06124: PTPN11; NbExp=4; IntAct=EBI-702104, EBI-297779;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18794797,
CC       ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20223987,
CC       ECO:0000269|PubMed:20861311, ECO:0000269|PubMed:34067457}; Single-pass
CC       type I membrane protein {ECO:0000255}. Cell projection, ruffle membrane
CC       {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein
CC       {ECO:0000255}. Cell projection, lamellipodium membrane
CC       {ECO:0000269|PubMed:19573808}; Single-pass type I membrane protein
CC       {ECO:0000255}. Cell junction, focal adhesion
CC       {ECO:0000269|PubMed:10655584}. Note=Present at regions of cell-cell
CC       contacts but also at the leading edge of migrating cells
CC       (PubMed:19573808, PubMed:20861311). Relocates from the plasma membrane
CC       to the cytoplasmic and perinuclear regions in cancer cells
CC       (PubMed:18794797). {ECO:0000269|PubMed:18794797,
CC       ECO:0000269|PubMed:19573808, ECO:0000269|PubMed:20861311,
CC       ECO:0000269|PubMed:26158630}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P29317-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P29317-2; Sequence=VSP_056014, VSP_056015;
CC   -!- TISSUE SPECIFICITY: Expressed in brain and glioma tissue and glioma
CC       cell lines (at protein level). Expressed most highly in tissues that
CC       contain a high proportion of epithelial cells, e.g. skin, intestine,
CC       lung, and ovary. {ECO:0000269|PubMed:17332925}.
CC   -!- INDUCTION: Up-regulated by UV irradiation via a TP53-independent, MAPK-
CC       dependent mechanism. {ECO:0000269|PubMed:18339848}.
CC   -!- PTM: Autophosphorylates. Phosphorylated on tyrosine upon binding and
CC       activation by EFNA1. Phosphorylated residues Tyr-588 and Tyr-594 are
CC       required for binding VAV2 and VAV3 while phosphorylated residues Tyr-
CC       735 and Tyr-930 are required for binding PI3-kinase p85 subunit
CC       (PIK3R1, PIK3R2 or PIK3R3). These phosphorylated residues are critical
CC       for recruitment of VAV2 and VAV3 and PI3-kinase p85 subunit which
CC       transduce downstream signaling to activate RAC1 GTPase and cell
CC       migration. Dephosphorylation of Tyr-930 by PTPRF prevents the
CC       interaction of EPHA2 with NCK1. Phosphorylated at Ser-897 by PKB;
CC       serum-induced phosphorylation which targets EPHA2 to the cell leading
CC       edge and stimulates cell migration. Phosphorylation by PKB is inhibited
CC       by EFNA1-activated EPHA2 which regulates PKB activity via a reciprocal
CC       regulatory loop. Phosphorylated at Ser-897 in response to TNF by
CC       RPS6KA1 and RPS6KA3; RPS6KA-EPHA2 signaling pathway controls cell
CC       migration (PubMed:26158630). Phosphorylated at Ser-897 by PKA; blocks
CC       cell retraction induced by EPHA2 kinase activity (PubMed:27385333).
CC       Dephosphorylated by ACP1. {ECO:0000269|PubMed:10655584,
CC       ECO:0000269|PubMed:18794797, ECO:0000269|PubMed:19573808,
CC       ECO:0000269|PubMed:23358419, ECO:0000269|PubMed:26158630,
CC       ECO:0000269|PubMed:27385333}.
CC   -!- PTM: Ubiquitinated by CHIP/STUB1. Ubiquitination is regulated by the
CC       HSP90 chaperone and regulates the receptor stability and activity
CC       through proteasomal degradation. ANKS1A prevents ubiquitination and
CC       degradation (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Cataract 6, multiple types (CTRCT6) [MIM:116600]: An
CC       opacification of the crystalline lens of the eye that frequently
CC       results in visual impairment or blindness. Opacities vary in
CC       morphology, are often confined to a portion of the lens, and may be
CC       static or progressive. CTRCT6 includes posterior polar and age-related
CC       cortical cataracts, among others. Posterior polar cataract is a
CC       subcapsular opacity, usually disk-shaped, located at the back of the
CC       lens. Age-related cortical cataract is a developmental punctate opacity
CC       restricted to the cortex. The cataract is white or cerulean, increases
CC       in number with age, but rarely affects vision.
CC       {ECO:0000269|PubMed:19005574, ECO:0000269|PubMed:19306328,
CC       ECO:0000269|PubMed:19649315, ECO:0000269|PubMed:22570727}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=Overexpressed in several cancer types and promotes
CC       malignancy. {ECO:0000269|PubMed:19573808}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Ephrin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/EPHA2ID40462ch1p36.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M59371; AAA53375.1; -; mRNA.
DR   EMBL; EU826606; ACF47642.1; -; mRNA.
DR   EMBL; AL451042; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471167; EAW51769.1; -; Genomic_DNA.
DR   EMBL; BC037166; AAH37166.1; -; mRNA.
DR   CCDS; CCDS169.1; -. [P29317-1]
DR   PIR; A36355; A36355.
DR   RefSeq; NP_004422.2; NM_004431.4. [P29317-1]
DR   PDB; 1MQB; X-ray; 2.30 A; A/B=596-900.
DR   PDB; 2E8N; NMR; -; A=902-976.
DR   PDB; 2K9Y; NMR; -; A/B=523-563.
DR   PDB; 2KSO; NMR; -; A=908-972.
DR   PDB; 2X10; X-ray; 3.00 A; A=27-534.
DR   PDB; 2X11; X-ray; 4.83 A; A=27-534.
DR   PDB; 3C8X; X-ray; 1.95 A; A=23-202.
DR   PDB; 3CZU; X-ray; 2.65 A; A=23-202.
DR   PDB; 3FL7; X-ray; 2.50 A; A=23-531.
DR   PDB; 3HEI; X-ray; 2.00 A; A/C/E/G/I/K/M/O=28-201.
DR   PDB; 3HPN; X-ray; 2.52 A; A/B/C/D/E/F=28-201.
DR   PDB; 3KKA; X-ray; 2.40 A; C/D/E=903-971.
DR   PDB; 3MBW; X-ray; 2.81 A; A=23-326.
DR   PDB; 3MX0; X-ray; 3.51 A; A/C=27-435.
DR   PDB; 3SKJ; X-ray; 2.50 A; E/F=23-202.
DR   PDB; 4P2K; X-ray; 1.50 A; A=590-876.
DR   PDB; 4PDO; X-ray; 2.10 A; A/B=590-876.
DR   PDB; 4TRL; X-ray; 2.45 A; A=590-876.
DR   PDB; 5EK7; X-ray; 1.90 A; A/B=583-876.
DR   PDB; 5I9U; X-ray; 1.89 A; A=596-900.
DR   PDB; 5I9V; X-ray; 1.46 A; A=596-900.
DR   PDB; 5I9W; X-ray; 1.36 A; A=596-900.
DR   PDB; 5I9X; X-ray; 1.43 A; A=596-900.
DR   PDB; 5I9Y; X-ray; 1.23 A; A=596-900.
DR   PDB; 5I9Z; X-ray; 1.70 A; A=596-900.
DR   PDB; 5IA0; X-ray; 1.95 A; A/B/C=596-900.
DR   PDB; 5IA1; X-ray; 2.04 A; A=596-900.
DR   PDB; 5IA2; X-ray; 1.62 A; A=596-900.
DR   PDB; 5IA3; X-ray; 1.79 A; A=596-900.
DR   PDB; 5IA4; X-ray; 1.80 A; A=596-900.
DR   PDB; 5IA5; X-ray; 1.78 A; A=596-900.
DR   PDB; 5NJZ; X-ray; 1.77 A; A=596-900.
DR   PDB; 5NK0; X-ray; 1.60 A; A=596-900.
DR   PDB; 5NK1; X-ray; 1.55 A; A=596-900.
DR   PDB; 5NK2; X-ray; 1.65 A; A=596-900.
DR   PDB; 5NK3; X-ray; 1.59 A; A=596-900.
DR   PDB; 5NK4; X-ray; 1.45 A; A=596-900.
DR   PDB; 5NK5; X-ray; 1.33 A; A=596-900.
DR   PDB; 5NK6; X-ray; 1.27 A; A=596-900.
DR   PDB; 5NK7; X-ray; 1.89 A; A=596-900.
DR   PDB; 5NK8; X-ray; 1.76 A; A=596-900.
DR   PDB; 5NK9; X-ray; 1.59 A; A=596-900.
DR   PDB; 5NKA; X-ray; 1.38 A; A=596-900.
DR   PDB; 5NKB; X-ray; 1.50 A; A=596-900.
DR   PDB; 5NKC; X-ray; 1.45 A; A=596-900.
DR   PDB; 5NKD; X-ray; 1.41 A; A=596-900.
DR   PDB; 5NKE; X-ray; 1.39 A; A=596-900.
DR   PDB; 5NKF; X-ray; 1.10 A; A=596-900.
DR   PDB; 5NKG; X-ray; 1.10 A; A=596-900.
DR   PDB; 5NKH; X-ray; 1.29 A; A=596-900.
DR   PDB; 5NKI; X-ray; 1.68 A; A=596-900.
DR   PDB; 5NZ9; NMR; -; A=945-969.
DR   PDB; 6B9L; X-ray; 3.20 A; A/B/C/D=27-200.
DR   PDB; 6F7M; NMR; -; A=945-969.
DR   PDB; 6F7N; NMR; -; A=951-963.
DR   PDB; 6FNF; X-ray; 1.56 A; A=596-900.
DR   PDB; 6FNG; X-ray; 1.04 A; A=596-900.
DR   PDB; 6FNH; X-ray; 1.38 A; A/B/C=596-900.
DR   PDB; 6HES; X-ray; 1.13 A; A=596-900.
DR   PDB; 6HET; X-ray; 1.21 A; A=596-900.
DR   PDB; 6HEU; X-ray; 1.72 A; A=596-900.
DR   PDB; 6HEV; X-ray; 1.28 A; A=596-900.
DR   PDB; 6HEW; X-ray; 1.27 A; A=596-900.
DR   PDB; 6HEX; X-ray; 1.41 A; A=596-900.
DR   PDB; 6HEY; X-ray; 1.37 A; A=596-900.
DR   PDB; 6NJZ; X-ray; 1.90 A; A/B=28-200.
DR   PDB; 6NK0; X-ray; 1.53 A; A/B=28-200.
DR   PDB; 6NK1; X-ray; 1.55 A; A/B=28-200.
DR   PDB; 6NK2; X-ray; 2.20 A; A/B=28-200.
DR   PDB; 6NKP; X-ray; 2.03 A; A/B=28-200.
DR   PDB; 6Q7B; X-ray; 1.01 A; A=596-900.
DR   PDB; 6Q7C; X-ray; 1.05 A; A=596-900.
DR   PDB; 6Q7D; X-ray; 0.98 A; A=596-900.
DR   PDB; 6Q7E; X-ray; 1.06 A; A=596-900.
DR   PDB; 6Q7F; X-ray; 1.20 A; A=596-900.
DR   PDB; 6Q7G; X-ray; 1.05 A; A=596-900.
DR   PDB; 6RW2; X-ray; 2.26 A; A=27-201.
DR   PDB; 7B7N; X-ray; 2.69 A; E=23-202.
DR   PDB; 7CZE; X-ray; 3.00 A; I/J/K/L=26-200.
DR   PDB; 7CZF; X-ray; 3.20 A; A/D=28-206.
DR   PDB; 7KJA; X-ray; 1.75 A; A/B=590-976.
DR   PDB; 7KJB; X-ray; 2.80 A; A=590-976.
DR   PDB; 7KJC; X-ray; 2.30 A; A/B=590-976.
DR   PDBsum; 1MQB; -.
DR   PDBsum; 2E8N; -.
DR   PDBsum; 2K9Y; -.
DR   PDBsum; 2KSO; -.
DR   PDBsum; 2X10; -.
DR   PDBsum; 2X11; -.
DR   PDBsum; 3C8X; -.
DR   PDBsum; 3CZU; -.
DR   PDBsum; 3FL7; -.
DR   PDBsum; 3HEI; -.
DR   PDBsum; 3HPN; -.
DR   PDBsum; 3KKA; -.
DR   PDBsum; 3MBW; -.
DR   PDBsum; 3MX0; -.
DR   PDBsum; 3SKJ; -.
DR   PDBsum; 4P2K; -.
DR   PDBsum; 4PDO; -.
DR   PDBsum; 4TRL; -.
DR   PDBsum; 5EK7; -.
DR   PDBsum; 5I9U; -.
DR   PDBsum; 5I9V; -.
DR   PDBsum; 5I9W; -.
DR   PDBsum; 5I9X; -.
DR   PDBsum; 5I9Y; -.
DR   PDBsum; 5I9Z; -.
DR   PDBsum; 5IA0; -.
DR   PDBsum; 5IA1; -.
DR   PDBsum; 5IA2; -.
DR   PDBsum; 5IA3; -.
DR   PDBsum; 5IA4; -.
DR   PDBsum; 5IA5; -.
DR   PDBsum; 5NJZ; -.
DR   PDBsum; 5NK0; -.
DR   PDBsum; 5NK1; -.
DR   PDBsum; 5NK2; -.
DR   PDBsum; 5NK3; -.
DR   PDBsum; 5NK4; -.
DR   PDBsum; 5NK5; -.
DR   PDBsum; 5NK6; -.
DR   PDBsum; 5NK7; -.
DR   PDBsum; 5NK8; -.
DR   PDBsum; 5NK9; -.
DR   PDBsum; 5NKA; -.
DR   PDBsum; 5NKB; -.
DR   PDBsum; 5NKC; -.
DR   PDBsum; 5NKD; -.
DR   PDBsum; 5NKE; -.
DR   PDBsum; 5NKF; -.
DR   PDBsum; 5NKG; -.
DR   PDBsum; 5NKH; -.
DR   PDBsum; 5NKI; -.
DR   PDBsum; 5NZ9; -.
DR   PDBsum; 6B9L; -.
DR   PDBsum; 6F7M; -.
DR   PDBsum; 6F7N; -.
DR   PDBsum; 6FNF; -.
DR   PDBsum; 6FNG; -.
DR   PDBsum; 6FNH; -.
DR   PDBsum; 6HES; -.
DR   PDBsum; 6HET; -.
DR   PDBsum; 6HEU; -.
DR   PDBsum; 6HEV; -.
DR   PDBsum; 6HEW; -.
DR   PDBsum; 6HEX; -.
DR   PDBsum; 6HEY; -.
DR   PDBsum; 6NJZ; -.
DR   PDBsum; 6NK0; -.
DR   PDBsum; 6NK1; -.
DR   PDBsum; 6NK2; -.
DR   PDBsum; 6NKP; -.
DR   PDBsum; 6Q7B; -.
DR   PDBsum; 6Q7C; -.
DR   PDBsum; 6Q7D; -.
DR   PDBsum; 6Q7E; -.
DR   PDBsum; 6Q7F; -.
DR   PDBsum; 6Q7G; -.
DR   PDBsum; 6RW2; -.
DR   PDBsum; 7B7N; -.
DR   PDBsum; 7CZE; -.
DR   PDBsum; 7CZF; -.
DR   PDBsum; 7KJA; -.
DR   PDBsum; 7KJB; -.
DR   PDBsum; 7KJC; -.
DR   AlphaFoldDB; P29317; -.
DR   BMRB; P29317; -.
DR   SMR; P29317; -.
DR   BioGRID; 108288; 266.
DR   CORUM; P29317; -.
DR   DIP; DIP-96N; -.
DR   IntAct; P29317; 172.
DR   MINT; P29317; -.
DR   STRING; 9606.ENSP00000351209; -.
DR   BindingDB; P29317; -.
DR   ChEMBL; CHEMBL2068; -.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB08896; Regorafenib.
DR   DrugCentral; P29317; -.
DR   GuidetoPHARMACOLOGY; 1822; -.
DR   GlyConnect; 777; 3 N-Linked glycans (1 site).
DR   GlyGen; P29317; 2 sites, 1 Asn glycan (1 site), 3 N-linked glycans (1 site).
DR   iPTMnet; P29317; -.
DR   PhosphoSitePlus; P29317; -.
DR   SwissPalm; P29317; -.
DR   BioMuta; EPHA2; -.
DR   DMDM; 229462861; -.
DR   CPTAC; CPTAC-1784; -.
DR   CPTAC; CPTAC-2783; -.
DR   EPD; P29317; -.
DR   jPOST; P29317; -.
DR   MassIVE; P29317; -.
DR   MaxQB; P29317; -.
DR   PaxDb; P29317; -.
DR   PeptideAtlas; P29317; -.
DR   PRIDE; P29317; -.
DR   ProteomicsDB; 54535; -. [P29317-1]
DR   ABCD; P29317; 26 sequenced antibodies.
DR   Antibodypedia; 4183; 1414 antibodies from 45 providers.
DR   DNASU; 1969; -.
DR   Ensembl; ENST00000358432.8; ENSP00000351209.5; ENSG00000142627.13. [P29317-1]
DR   GeneID; 1969; -.
DR   KEGG; hsa:1969; -.
DR   MANE-Select; ENST00000358432.8; ENSP00000351209.5; NM_004431.5; NP_004422.2.
DR   UCSC; uc001aya.2; human. [P29317-1]
DR   CTD; 1969; -.
DR   DisGeNET; 1969; -.
DR   GeneCards; EPHA2; -.
DR   HGNC; HGNC:3386; EPHA2.
DR   HPA; ENSG00000142627; Tissue enhanced (esophagus).
DR   MalaCards; EPHA2; -.
DR   MIM; 116600; phenotype.
DR   MIM; 176946; gene.
DR   neXtProt; NX_P29317; -.
DR   OpenTargets; ENSG00000142627; -.
DR   Orphanet; 98991; Early-onset nuclear cataract.
DR   Orphanet; 98993; Early-onset posterior polar cataract.
DR   Orphanet; 441447; Early-onset posterior subcapsular cataract.
DR   Orphanet; 98994; Total early-onset cataract.
DR   PharmGKB; PA27818; -.
DR   VEuPathDB; HostDB:ENSG00000142627; -.
DR   eggNOG; KOG0196; Eukaryota.
DR   GeneTree; ENSGT00940000160786; -.
DR   HOGENOM; CLU_000288_141_4_1; -.
DR   InParanoid; P29317; -.
DR   OMA; MPIYMYT; -.
DR   OrthoDB; 172471at2759; -.
DR   PhylomeDB; P29317; -.
DR   TreeFam; TF315608; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P29317; -.
DR   Reactome; R-HSA-2682334; EPH-Ephrin signaling.
DR   Reactome; R-HSA-3928663; EPHA-mediated growth cone collapse.
DR   Reactome; R-HSA-3928665; EPH-ephrin mediated repulsion of cells.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013408; RHOG GTPase cycle.
DR   Reactome; R-HSA-9013420; RHOU GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   Reactome; R-HSA-9013424; RHOV GTPase cycle.
DR   Reactome; R-HSA-9696264; RND3 GTPase cycle.
DR   Reactome; R-HSA-9696270; RND2 GTPase cycle.
DR   Reactome; R-HSA-9696273; RND1 GTPase cycle.
DR   SignaLink; P29317; -.
DR   SIGNOR; P29317; -.
DR   BioGRID-ORCS; 1969; 13 hits in 1116 CRISPR screens.
DR   ChiTaRS; EPHA2; human.
DR   EvolutionaryTrace; P29317; -.
DR   GeneWiki; EPH_receptor_A2; -.
DR   GenomeRNAi; 1969; -.
DR   Pharos; P29317; Tclin.
DR   PRO; PR:P29317; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P29317; protein.
DR   Bgee; ENSG00000142627; Expressed in lower esophagus mucosa and 141 other tissues.
DR   ExpressionAtlas; P29317; baseline and differential.
DR   Genevisible; P29317; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IDA:UniProtKB.
DR   GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0031256; C:leading edge membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070160; C:tight junction; IDA:ARUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0019838; F:growth factor binding; IPI:ARUK-UCL.
DR   GO; GO:0140677; F:molecular function activator activity; EXP:DisProt.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005005; F:transmembrane-ephrin receptor activity; IBA:GO_Central.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0090630; P:activation of GTPase activity; IMP:UniProtKB.
DR   GO; GO:0048320; P:axial mesoderm formation; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IEA:Ensembl.
DR   GO; GO:0046849; P:bone remodeling; ISS:UniProtKB.
DR   GO; GO:0060444; P:branching involved in mammary gland duct morphogenesis; ISS:UniProtKB.
DR   GO; GO:0046058; P:cAMP metabolic process; IMP:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0048870; P:cell motility; IMP:UniProtKB.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0048013; P:ephrin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IDA:UniProtKB.
DR   GO; GO:0030216; P:keratinocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0070309; P:lens fiber cell morphogenesis; ISS:UniProtKB.
DR   GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISS:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0032682; P:negative regulation of chemokine production; IEA:Ensembl.
DR   GO; GO:1901491; P:negative regulation of lymphangiogenesis; IEA:Ensembl.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0021915; P:neural tube development; IEA:Ensembl.
DR   GO; GO:0060035; P:notochord cell development; IEA:Ensembl.
DR   GO; GO:0014028; P:notochord formation; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0030316; P:osteoclast differentiation; ISS:UniProtKB.
DR   GO; GO:1904238; P:pericyte cell differentiation; IEA:Ensembl.
DR   GO; GO:1903348; P:positive regulation of bicellular tight junction assembly; IMP:ARUK-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:ARUK-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:1903078; P:positive regulation of protein localization to plasma membrane; IMP:UniProtKB.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0043491; P:protein kinase B signaling; IDA:UniProtKB.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IMP:ARUK-UCL.
DR   GO; GO:0045765; P:regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0033628; P:regulation of cell adhesion mediated by integrin; IDA:UniProtKB.
DR   GO; GO:0070372; P:regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0010591; P:regulation of lamellipodium assembly; IMP:UniProtKB.
DR   GO; GO:0070848; P:response to growth factor; IMP:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   CDD; cd10480; EphR_LBD_A2; 1.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 1.10.150.50; -; 1.
DR   Gene3D; 2.60.40.10; -; 2.
DR   InterPro; IPR027936; Eph_TM.
DR   InterPro; IPR034263; EphA2_rcpt_lig-bd.
DR   InterPro; IPR001090; Ephrin_rcpt_lig-bd_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR008979; Galactose-bd-like_sf.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001660; SAM.
DR   InterPro; IPR013761; SAM/pointed_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016257; Tyr_kinase_ephrin_rcpt.
DR   InterPro; IPR001426; Tyr_kinase_rcpt_V_CS.
DR   Pfam; PF14575; EphA2_TM; 1.
DR   Pfam; PF01404; Ephrin_lbd; 1.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00536; SAM_1; 1.
DR   PIRSF; PIRSF000666; TyrPK_ephrin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00615; EPH_lbd; 1.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00454; SAM; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF47769; SSF47769; 1.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF49785; SSF49785; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS51550; EPH_LBD; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00790; RECEPTOR_TYR_KIN_V_1; 1.
DR   PROSITE; PS00791; RECEPTOR_TYR_KIN_V_2; 1.
DR   PROSITE; PS50105; SAM_DOMAIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; Apoptosis; ATP-binding;
KW   Cataract; Cell adhesion; Cell junction; Cell membrane; Cell projection;
KW   Differentiation; Disease variant; Disulfide bond; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome;
KW   Repeat; Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..976
FT                   /note="Ephrin type-A receptor 2"
FT                   /id="PRO_0000016800"
FT   TOPO_DOM        24..537
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        538..558
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        559..976
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          28..206
FT                   /note="Eph LBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00883"
FT   DOMAIN          328..432
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          438..529
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          613..875
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          904..968
FT                   /note="SAM"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00184"
FT   REGION          1..206
FT                   /note="Mediates interaction with CLDN4"
FT                   /evidence="ECO:0000269|PubMed:16236711"
FT   REGION          606..906
FT                   /note="Mediates interaction with ARHGEF16 and ELMO2"
FT                   /evidence="ECO:0000269|PubMed:20679435"
FT   REGION          886..976
FT                   /note="Negatively regulates interaction with ARHGEF16"
FT                   /evidence="ECO:0000269|PubMed:20679435"
FT   MOTIF           974..976
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        739
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         619..627
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         646
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         570
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:19369195"
FT   MOD_RES         575
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         579
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         588
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         594
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03145"
FT   MOD_RES         628
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         647
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195"
FT   MOD_RES         735
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:Q03145"
FT   MOD_RES         772
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:Q03145"
FT   MOD_RES         869
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         892
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         897
FT                   /note="Phosphoserine; by PKB/AKT1, RPS6KA1, RPS6KA3 AND
FT                   PKA"
FT                   /evidence="ECO:0000269|PubMed:19573808,
FT                   ECO:0000269|PubMed:26158630, ECO:0000269|PubMed:27385333,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         901
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:27385333,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         921
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         930
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:23358419"
FT   CARBOHYD        407
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        435
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   DISULFID        70..188
FT   DISULFID        105..115
FT   VAR_SEQ         477..497
FT                   /note="GDSNSYNVRRTEGFSVTLDDL -> VTPRGAGLALAGPTAGDRLVT (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056014"
FT   VAR_SEQ         498..976
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:18593464"
FT                   /id="VSP_056015"
FT   VARIANT         99
FT                   /note="K -> N (in dbSNP:rs1058372)"
FT                   /id="VAR_055989"
FT   VARIANT         391
FT                   /note="G -> R (in dbSNP:rs34192549)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042121"
FT   VARIANT         511
FT                   /note="T -> M (in dbSNP:rs55747232)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042122"
FT   VARIANT         568
FT                   /note="R -> H (in dbSNP:rs56198600)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042123"
FT   VARIANT         631
FT                   /note="M -> T (in dbSNP:rs34021505)"
FT                   /id="VAR_055990"
FT   VARIANT         721
FT                   /note="R -> Q (in CTRCT6; retained in the cytoplasm and
FT                   constitutively active it alters EPHA2 signaling;
FT                   dbSNP:rs116506614)"
FT                   /evidence="ECO:0000269|PubMed:19649315"
FT                   /id="VAR_062532"
FT   VARIANT         777
FT                   /note="G -> S (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs922655349)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042124"
FT   VARIANT         876
FT                   /note="R -> H (in dbSNP:rs35903225)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042125"
FT   VARIANT         940
FT                   /note="T -> I (in CTRCT6; reduced protein stability and
FT                   reduced ability to stimulate cell migration in absence of
FT                   its ephrin ligand; dbSNP:rs137853200)"
FT                   /evidence="ECO:0000269|PubMed:19306328,
FT                   ECO:0000269|PubMed:22570727"
FT                   /id="VAR_058907"
FT   VARIANT         948
FT                   /note="G -> W (in CTRCT6; reduced protein stability and
FT                   reduced ability to stimulate cell migration in absence of
FT                   its ephrin ligand; dbSNP:rs137853199)"
FT                   /evidence="ECO:0000269|PubMed:19005574,
FT                   ECO:0000269|PubMed:22570727"
FT                   /id="VAR_058908"
FT   MUTAGEN         103
FT                   /note="R->E: Significantly reduced response to EFNA1."
FT                   /evidence="ECO:0000269|PubMed:19525919"
FT   MUTAGEN         646
FT                   /note="K->M: Loss of kinase activity."
FT                   /evidence="ECO:0000269|PubMed:16236711"
FT   MUTAGEN         739
FT                   /note="D->N: Increases serum-induced chemotaxis. Loss of
FT                   EFNA1-dependent regulation of cell migration."
FT                   /evidence="ECO:0000269|PubMed:19573808"
FT   MUTAGEN         897
FT                   /note="S->A,D: Loss of serum-induced phosphorylation by
FT                   PKB. Loss of serum-induced chemotaxis."
FT                   /evidence="ECO:0000269|PubMed:19573808"
FT   CONFLICT        94..99
FT                   /note="IFIELK -> NNFELN (in Ref. 1; AAA53375)"
FT                   /evidence="ECO:0000305"
FT   STRAND          28..33
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   HELIX           34..37
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          44..47
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   TURN            48..50
FT                   /evidence="ECO:0007829|PDB:6NK1"
FT   STRAND          53..57
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          59..62
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          64..70
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          73..75
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          79..82
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          92..103
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   HELIX           105..107
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          108..110
FT                   /evidence="ECO:0007829|PDB:3HEI"
FT   TURN            112..114
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          119..128
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   HELIX           136..138
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          140..145
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          148..151
FT                   /evidence="ECO:0007829|PDB:6RW2"
FT   HELIX           153..157
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          164..170
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          175..199
FT                   /evidence="ECO:0007829|PDB:6NK0"
FT   STRAND          204..206
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          209..211
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          218..221
FT                   /evidence="ECO:0007829|PDB:3MBW"
FT   STRAND          224..227
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          238..240
FT                   /evidence="ECO:0007829|PDB:3MBW"
FT   STRAND          244..247
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          253..257
FT                   /evidence="ECO:0007829|PDB:3MBW"
FT   STRAND          266..269
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          272..275
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          286..288
FT                   /evidence="ECO:0007829|PDB:3MBW"
FT   STRAND          295..298
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          335..338
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          343..348
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          361..369
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          376..378
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          384..387
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          389..392
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          394..400
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          407..415
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   HELIX           419..421
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          427..433
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          441..446
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          453..457
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   TURN            460..465
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          467..475
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          483..493
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          502..510
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   STRAND          522..525
FT                   /evidence="ECO:0007829|PDB:3FL7"
FT   HELIX           536..556
FT                   /evidence="ECO:0007829|PDB:2K9Y"
FT   STRAND          557..561
FT                   /evidence="ECO:0007829|PDB:2K9Y"
FT   HELIX           591..594
FT                   /evidence="ECO:0007829|PDB:5EK7"
FT   HELIX           597..600
FT                   /evidence="ECO:0007829|PDB:4PDO"
FT   TURN            601..604
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           610..612
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   STRAND          613..622
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   STRAND          625..632
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           635..637
FT                   /evidence="ECO:0007829|PDB:5NKH"
FT   STRAND          641..648
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           654..669
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   STRAND          678..682
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   STRAND          684..693
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           700..706
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   TURN            707..709
FT                   /evidence="ECO:0007829|PDB:6Q7E"
FT   HELIX           713..732
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           742..744
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   STRAND          745..747
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   STRAND          753..755
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           762..766
FT                   /evidence="ECO:0007829|PDB:5NKF"
FT   STRAND          770..772
FT                   /evidence="ECO:0007829|PDB:5NKF"
FT   STRAND          776..778
FT                   /evidence="ECO:0007829|PDB:5NKH"
FT   HELIX           781..783
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           786..791
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           796..811
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   TURN            817..820
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           823..831
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           844..853
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           858..860
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           864..876
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   HELIX           878..881
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   STRAND          882..884
FT                   /evidence="ECO:0007829|PDB:6Q7D"
FT   STRAND          892..894
FT                   /evidence="ECO:0007829|PDB:7KJB"
FT   HELIX           909..915
FT                   /evidence="ECO:0007829|PDB:7KJA"
FT   HELIX           919..921
FT                   /evidence="ECO:0007829|PDB:7KJA"
FT   HELIX           922..927
FT                   /evidence="ECO:0007829|PDB:7KJA"
FT   HELIX           933..936
FT                   /evidence="ECO:0007829|PDB:7KJA"
FT   HELIX           941..946
FT                   /evidence="ECO:0007829|PDB:7KJA"
FT   HELIX           952..969
FT                   /evidence="ECO:0007829|PDB:7KJA"
SQ   SEQUENCE   976 AA;  108266 MW;  845D7E1BBCCAACCC CRC64;
     MELQAARACF ALLWGCALAA AAAAQGKEVV LLDFAAAGGE LGWLTHPYGK GWDLMQNIMN
     DMPIYMYSVC NVMSGDQDNW LRTNWVYRGE AERIFIELKF TVRDCNSFPG GASSCKETFN
     LYYAESDLDY GTNFQKRLFT KIDTIAPDEI TVSSDFEARH VKLNVEERSV GPLTRKGFYL
     AFQDIGACVA LLSVRVYYKK CPELLQGLAH FPETIAGSDA PSLATVAGTC VDHAVVPPGG
     EEPRMHCAVD GEWLVPIGQC LCQAGYEKVE DACQACSPGF FKFEASESPC LECPEHTLPS
     PEGATSCECE EGFFRAPQDP ASMPCTRPPS APHYLTAVGM GAKVELRWTP PQDSGGREDI
     VYSVTCEQCW PESGECGPCE ASVRYSEPPH GLTRTSVTVS DLEPHMNYTF TVEARNGVSG
     LVTSRSFRTA SVSINQTEPP KVRLEGRSTT SLSVSWSIPP PQQSRVWKYE VTYRKKGDSN
     SYNVRRTEGF SVTLDDLAPD TTYLVQVQAL TQEGQGAGSK VHEFQTLSPE GSGNLAVIGG
     VAVGVVLLLV LAGVGFFIHR RRKNQRARQS PEDVYFSKSE QLKPLKTYVD PHTYEDPNQA
     VLKFTTEIHP SCVTRQKVIG AGEFGEVYKG MLKTSSGKKE VPVAIKTLKA GYTEKQRVDF
     LGEAGIMGQF SHHNIIRLEG VISKYKPMMI ITEYMENGAL DKFLREKDGE FSVLQLVGML
     RGIAAGMKYL ANMNYVHRDL AARNILVNSN LVCKVSDFGL SRVLEDDPEA TYTTSGGKIP
     IRWTAPEAIS YRKFTSASDV WSFGIVMWEV MTYGERPYWE LSNHEVMKAI NDGFRLPTPM
     DCPSAIYQLM MQCWQQERAR RPKFADIVSI LDKLIRAPDS LKTLADFDPR VSIRLPSTSG
     SEGVPFRTVS EWLESIKMQQ YTEHFMAAGY TAIEKVVQMT NDDIKRIGVR LPGHQKRIAY
     SLLGLKDQVN TVGIPI
//
